Historical record - last NADAC publication: 11/18/2020

Product Information

IMATINIB MESYLATE 400 MG TAB is a generic product labeled by Ascend Laboratories, LLC, priced at $6.5733 per EA under NDC 67877063430. Its NADAC has been published 87 times since Apr 10, 2019.

The High Outlier badge above means this manufacturer's average price in the imatinib mesylate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

IMATINIB MESYLATE 400 MG TAB

imatinib mesylate
$6.5733per EA
High Outlier

Strength

400 mg/1

NDC

67877063430

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Last Updated

11/18/2020

Active Ingredients

IMATINIB MESYLATE

Approval Type

Generic (ANDA)

FDA Application

ANDA208302

On Market Since

2/1/2019

Pharmacological Classes

Kinase Inhibitor
Protein Kinase Inhibitors

Price Statistics

The NADAC for IMATINIB MESYLATE 400 MG TAB has been published 87 times since Apr 10, 2019, and over the history we have for it it has declined 57.8%. The table below summarizes its recorded NADAC range and movement.

Current price$6.5733 per EA
All-time high$16.3963 (Jul 10, 2019)
All-time low$5.8096 (Feb 19, 2020)
Median price$9.3296
Average price$9.9565
Largest weekly change+100.9% (Mar 18, 2020)
Weeks tracked87
Tracking sinceApr 10, 2019

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

0.0%

3Y

0.0%

5Y

0.0%

All

-57.8%

Generic Alternatives

The matcher finds 6 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 6 manufacturers (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 69% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of IMATINIB MESYLATE 400 MG TAB?

The current National Average Drug Acquisition Cost (NADAC) for IMATINIB MESYLATE 400 MG TAB, manufactured by Ascend Laboratories, LLC, is $6.5733 per EA (NDC 67877063430), effective Dec 2, 2020.

How has the price of IMATINIB MESYLATE 400 MG TAB changed over time?

Over the history we have for it, the NADAC for IMATINIB MESYLATE 400 MG TAB has declined 57.8%. It has been tracked across 87 weekly CMS publications since Apr 10, 2019.

What are the highest and lowest recorded NADAC prices for IMATINIB MESYLATE 400 MG TAB?

Since Apr 10, 2019, the NADAC for IMATINIB MESYLATE 400 MG TAB has ranged from a low of $5.8096 (Feb 19, 2020) to a high of $16.3963 (Jul 10, 2019), with a median of $9.3296 per EA.

Are there cheaper alternatives to IMATINIB MESYLATE 400 MG TAB?

Yes. 6 NADAC-published products share the same active ingredient, strength, and dosage form. The lowest-priced option, IMATINIB MESYLATE 400 MG TAB, is $2.0356 per EA — about 69% below IMATINIB MESYLATE 400 MG TAB.

Who manufactures IMATINIB MESYLATE 400 MG TAB?

IMATINIB MESYLATE 400 MG TAB (NDC 67877063430) is labeled by Ascend Laboratories, LLC, and CMS classifies it as a generic product.